Shares of Moderna (NASDAQ: MRNA) climbed 5% on Thursday as the biotech progressed toward a major vaccine development milestone.
Late on Thursday, the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee recommended authorization of Moderna's vaccine candidate for emergency use. The advisory committee helps assure vaccines are safe for the public. The FDA isn't required to follow its recommendations, but typically does.
Moderna's stock popped on Thursday. Image source: Getty Images.
Source Fool.com